Table 3

Discontinuation summary for abatacept and tocilizumab*

Abatacept (n=150)Tocilizumab (n=178)
Follow-up period, median (range)*37 weeks (3–148)24 weeks (2–65)
Total number of treatment withdrawals (n (%))67 (45)39 (22)
Reasons for withdrawal†:
 No effect (n (%))54 (36)20 (11)
 AEs (n (%))17 (11)12 (7)
 Remission (n (%))1 (1)1 (1)
 Others (n (%))3 (2)7 (4)

  • ↵* Notice that the follow-up time is longer for abatacept than for tocilizumab.

  • ↵† For abatacept and tocilizumab, seven and one treatments were withdrawn owing to both no effect and AEs, respectively.

    AEs, adverse events.